New and Emerging Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: What is New and What is to Come | Zendy

Jacqueline Nicholas | Zendy; Bethanie Morgan-Followell | Zendy; David Pitt | Zendy; Michael K. Racke | Zendy; Aaron Boster | Zendy

Open Access

New and Emerging Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: What is New and What is to Come

Author(s) -

Jacqueline Nicholas,

Bethanie Morgan-Followell,

David Pitt,

Michael K. Racke,

Aaron Boster

Publication year - 2012

Publication title -

journal of central nervous system disease

Language(s) - English

Resource type - Journals

ISSN - 1179-5735

DOI - 10.4137/jcnsd.s6692

Subject(s) - teriflunomide , natalizumab , ocrelizumab , fingolimod , medicine , multiple sclerosis , daclizumab , alemtuzumab , mitoxantrone , glatiramer acetate , relapsing remitting , ofatumumab , clinical trial , biosimilar , immunology , monoclonal antibody , rituximab , transplantation , antibody , chemotherapy , lymphoma

The therapeutic landscape for multiple sclerosis (MS) is rapidly changing. Currently, there are eight FDA approved disease modifying therapies for MS including: IFN-β-1a (Avonex, Rebif), IFN-β-1b (Betaseron, Extavia), glatiramer acetate (Copaxone), mitoxantrone (Novantrone), natalizumab (Tysabri), and fingolimod (Gilenya). This review will highlight the experience to date and key clinical trials of the newest FDA approved agents, natalizumab and fingolimod. It will also review available efficacy and safety data on several promising therapies under active investigation including four monoclonal antibody therapies: alemtuzumab, daclizumab, ocrelizumab and ofatumumab and three oral agents: BG12, laquinimod, and teriflunomide. To conclude, we will discuss where each of these new therapies may best fit into treatment algorithms.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research